Difference between revisions of "Dalteparin (Fragmin)"
Jump to navigation
Jump to search
m (Text replacement - "[[File:" to "[[:File:") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Low molecular weight heparin, binds to antithrombin III, accelerating its activity and inhibiting factor Xa and thrombin.<ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=2293 Dalteparin (Fragmin) package insert]</ref><ref>[[:File:Dalteparin.pdf | Dalteparin (Fragmin) package insert (locally hosted backup)]]</ref><ref>[https://www. | + | Class/mechanism: Low molecular weight heparin, binds to antithrombin III, accelerating its activity and inhibiting factor Xa and thrombin.<ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=2293 Dalteparin (Fragmin) package insert]</ref><ref>[[:File:Dalteparin.pdf | Dalteparin (Fragmin) package insert (locally hosted backup)]]</ref><ref>[https://www.pfizer.com/products/product-detail/fragmin Fragmin manufacturer's website]</ref> |
<br>Route: SC | <br>Route: SC | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Patient drug information== | ==Patient drug information== | ||
| Line 11: | Line 11: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *12 | + | *1994-12-22: Initial approval for the prophylaxis of [[Venous thromboembolism|deep vein thrombosis (DVT)]], which may lead to pulmonary embolism (PE) in patients undergoing hip replacement surgery. |
| − | *Subsequently approved for prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness and extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months. | + | *Uncertain date: Subsequently approved for prophylaxis of [[Venous thromboembolism|deep vein thrombosis (DVT)]] in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness and extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months. |
| − | * | + | *2019-05-16: Approved to reduce the recurrence of symptomatic [[Venous thromboembolism|venous thromboembolism (VTE)]] in pediatric patients 1 month of age and older. |
==Also known as== | ==Also known as== | ||
Latest revision as of 01:05, 29 June 2024
General information
Class/mechanism: Low molecular weight heparin, binds to antithrombin III, accelerating its activity and inhibiting factor Xa and thrombin.[1][2][3]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Patient drug information
- Brief patient counseling information can be found in the Dalteparin (Fragmin) package insert[1]
- Dalteparin (Fragmin) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1994-12-22: Initial approval for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip replacement surgery.
- Uncertain date: Subsequently approved for prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness and extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months.
- 2019-05-16: Approved to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients 1 month of age and older.
Also known as
- Brand names: Daltepan, Daltepin, Fluzepamin, Fragmin, Fragmine, Fragminject, Fresubaru, Hepachron, Hepagumin, Ligofragmin, Low Liquemin, Resolmin